UroGen Pharma Earnings
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$0.38
UroGen Pharma earnings summary
UroGen Pharma is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $0.38. In its most recent report on Aug 5, 2026 (Q2 2026), URGN posted EPS of $-0.28. Revenue for the quarter was $72.5 million.
Across the last 16 reports, URGN shares moved an average of 8.4% (in either direction) in the first trading session after results, rising 7 times and falling 9 times.
Summary generated from market data by MetaCap's automated system. Methodology
URGN earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $-0.28 | — | +2.7% |
| May 6, 2026 | — | $-0.47 | — | -2.1% |
| Mar 2, 2026 | — | $-0.53 | — | -9.9% |
| Nov 6, 2025 | — | $-0.69 | — | +2.2% |
| Aug 7, 2025 | — | $-1.05 | — | +11.1% |
| May 12, 2025 | — | $-0.92 | — | -42.7% |
| Mar 10, 2025 | — | $-0.80 | — | +9.6% |
| Nov 6, 2024 | — | $-0.51 | — | -7.7% |
| Aug 13, 2024 | — | $-0.82 | — | -4.3% |
| May 13, 2024 | — | $-0.87 | — | +0.2% |
| Nov 14, 2023 | — | $-0.68 | — | +3.9% |
| Aug 10, 2023 | — | $-1.03 | — | -13.9% |
| May 11, 2023 | — | $-1.30 | — | -4.3% |
| Mar 24, 2023 | — | $-1.25 | — | +10.1% |
| Nov 10, 2022 | — | $-1.13 | — | -5.8% |
| Aug 11, 2022 | — | $-1.18 | — | -3.5% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.